Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1973 1
1974 1
1980 1
1981 2
1982 2
1983 2
1984 3
1985 8
1986 5
1987 12
1988 8
1989 9
1990 11
1991 13
1992 14
1993 7
1994 12
1995 10
1996 9
1997 8
1998 9
1999 9
2000 8
2001 9
2002 6
2003 6
2004 8
2005 6
2006 7
2007 5
2008 8
2009 15
2010 8
2011 8
2012 14
2013 12
2014 10
2015 17
2016 16
2017 16
2018 18
2019 13
2020 11
2021 12
2022 9
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Results by year

Filters applied: . Clear all
Page 1
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, Eckstein M. Klümper N, et al. Among authors: wirtz rm. Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764. Clin Cancer Res. 2023. PMID: 36534531 Free PMC article.
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
Cox A, Klümper N, Stein J, Sikic D, Breyer J, Bolenz C, Roghmann F, Erben P, Wirtz RM, Wullich B, Ritter M, Hölzel M, Schwamborn K, Horn T, Gschwend J, Hartmann A, Weichert W, Erlmeier F, Eckstein M. Cox A, et al. Among authors: wirtz rm. Eur Urol. 2024 Apr;85(4):328-332. doi: 10.1016/j.eururo.2023.03.020. Epub 2023 Apr 6. Eur Urol. 2024. PMID: 37031005 Free article.
DEGRO 2004 : 10. Jahreskongress der Deutschen Gesellschaft für Radioonkologie.
Wendt TG, Gademann G, Pambor C, Grießbach I, von Specht H, Martin T, Baltas D, Kurek R, Röddiger S, Tunn UW, Zamboglou N, Eich HT, Staar S, Gossmann A, Hansemann K, Semrau R, Skripnitchenko R, Diehl V, Müller RP, Sehlen S, Willich N, Rühl U, Lukas P, Dühmke E, Engel K, Tabbert E, Bolck M, Knaack S, Annweiler H, Krempien R, Hoppe H, Harms W, Daeuber S, Schorr O, Treiber M, Debus J, Alber M, Paulsen F, Birkner M, Bakai A, Belka C, Budach W, Grosser KH, Kramer R, Kober B, Reinert M, Schneider P, Hertel A, Feldmann H, Csere P, Hoinkis C, Rothe G, Zahn P, Alheit H, Cavanaugh SX, Kupelian P, Reddy C, Pollock B, Fuss M, Roeddiger S, Dannenberg T, Rogge B, Drechsler D, Herrmann T, Alberti W, Schwarz R, Graefen M, Krüll A, Rudat V, Huland H, Fehr C, Baum C, Glocker S, Nüsslin F, Heil T, Lemnitzer H, Knips M, Baumgart O, Thiem W, Kloetzer KH, Hoffmann L, Neu B, Hültenschmidt B, Sautter-Bihl ML, Micke O, Seegenschmiedt MH, Köppen D, Klautke G, Fietkau R, Schultze J, Schlichting G, Koltze H, Kimmig B, Glatzel M, Fröhlich D, Bäsecke S, Krauß A, Strauß D, Buth KJ, Böhme R, Oehler W, Bottke D, Keilholz U, Heufelder K, Wiegel T, Hinkelbein W, Rödel C, Papadopoulos T, Munnes M, Wirtz R, Sau… See abstract for full author list ➔ Wendt TG, et al. Among authors: wirtz r. Strahlenther Onkol. 2004 Jun;180 Suppl 1:5-87. doi: 10.1007/BF03356734. Strahlenther Onkol. 2004. PMID: 27137922 German. No abstract available.
[Differential diagnosis and treatment of pituitary adenomas].
Hlaváč M, Sommer F, Karpel-Massler G, Wirtz R, Hoffmann T, Paľa A. Hlaváč M, et al. Among authors: wirtz r. HNO. 2019 Apr;67(4):307-318. doi: 10.1007/s00106-019-0629-3. HNO. 2019. PMID: 30790007 Review. German.
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, Sikic D, Wullich B, Bolenz C, Roghmann F, Hölzel M, Ritter M, Strieth S, Hartmann A, Erben P, Wirtz RM, Landsberg J, Dietrich D, Eckstein M. Klümper N, et al. Among authors: wirtz rm. Oncoimmunology. 2023 Oct 19;12(1):2267744. doi: 10.1080/2162402X.2023.2267744. eCollection 2023. Oncoimmunology. 2023. PMID: 37868689 Free PMC article.
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Erlmeier F, et al. Among authors: wirtz rm. Eur Urol. 2023 Feb;83(2):133-142. doi: 10.1016/j.eururo.2022.10.020. Epub 2022 Nov 10. Eur Urol. 2023. PMID: 36372626 Free article.
384 results